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Metastasis of hepatocellular carcinoma (HCC) to the ovary 
is notably rare. We present a case of HCC metastasis to the 
ovary with a review of the literature, which includes only 7 
reported cases. A 43-year-old hepatitis B virus carrier was 
admitted with a right ovarian cystic mass. She had been 
diagnosed with HCC 2 years prior, for which she underwent 
transarterial chemoembolization followed by right posterior 
sectionectomy. Eight months after the hepatectomy, the ﬁ  rst 
intrahepatic recurrence was detected and treated with trans-
arterial chemoembolization. An additional intrahepatic recur-
rence occurred 12 months after transarterial chemoemboli-
zation and was managed with left medial sectionectomy and 
intra-operative radiofrequency ablation. Over the following 3 
months, the patient developed elevated alpha-fetoprotein, 
and positron emission tomography showed a cystic mass in 
the right side of the pelvic cavity with focal hypermetabolic 
activity, which suggested a site of recurrent HCC. An explor-
atory laparotomy was performed, and a soft, ovoid cystic 
mass was identiﬁ  ed in the right ovary. There was no evidence 
of metastases in the liver, left ovary, or peritoneum. Because 
of the absence of tumor on the surface of the ovary and 
the lack of peritoneal seeding, the mode of metastasis was 
thought to be hematogenous. Therefore, a right salphingo-
oophorectomy was performed. The pathological features 
showed metastatic HCC with clear resection margins. Al-
though metastasis of HCC to the ovary is very rare, it should 
be suspected in a female patient with a lower abdominal 
mass and an elevated serum AFP level in the absence of 
other demonstrable metastases. (Gut Liver 2011;5:543-547)
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INTRODUCTION
Hepatocellular carcinoma (HCC) spreads via the hematoge-
nous route, the lymphatic route, or by direct invasion into adja-
cent organs.
1 The common extrahepatic metastatic sites of HCC 
are the lungs, peritoneum, adrenal glands, and bone,
2 although 
there are rare reports of metastases to the heart,
3 nasal cavity,
4 
orbital cavity,
5 skin,
6 external auditory canals,
7 and pharynx.
8 
The ovary is a rare site of metastasis for HCC, which was first 
reported in 1983.
9 In the English literature, there have been 6 
reported cases of metastatic HCC to the ovary and 4 cases re-
ported in the Korean literature. We present a case of metastatic 
HCC to the ovary with a review of the literature. 
CASE REPORT
A 43-year-old woman with a history of HCC secondary to 
chronic infection with hepatitis B virus (HBV) was admitted to 
the hospital for evaluation of a right ovarian cystic mass. She 
also had a family history of HBV in two of her siblings. She was 
diagnosed with HCC 2 years ago and underwent transarterial 
chemoembolization (TACE), followed by right posterior sectio-
nectomy. Eight months after the hepatectomy, the first intra-
hepatic recurrence was detected, which was treated with TACE. 
An additional intrahepatic recurrence occurred 12 months after 
TACE, which was managed with left medial sectionectomy and 
intra-operative radiofrequency ablation. 
During the 3-month follow-up period after the second hepa-
tectomy, the patient developed an elevated alpha-fetoprotein 
(AFP; 336,520 ng/μL [normal range, 0 to 7 ng/μL]). However, a 
liver dynamic computed tomography (CT) and chest CT showed 
no evidence of recurrent HCC. A positron emission tomography 
(PET) showed a hypermetabolic lesion (max SUV=4.5 in the 544  Gut and Liver, Vol. 5, No. 4, December 2011
right side of pelvic cavity), suggesting the site of recurrent HCC. 
Further examination of the abdominopelvic CT revealed a right 
ovarian cystic mass (Fig. 1).
Since the metastasis was limited to the right ovary without 
evidence of widespread recurrence, she was recommended to 
undergo an exploratory laparotomy with removal of the right 
ovarian mass. At laparotomy, there was no evidence of metas-
tases in the liver, left ovary, or peritoneum. A soft, ovoid, cystic 
mass was identified in the right ovary and the frozen section 
confirmed metastatic HCC. Because of the absence of tumor on 
the surface of the ovary and the lack of peritoneal seeding, the 
mode of metastasis was thought to be hematogenous. Therefore, 
a right salphingo-oophorectomy (SO) was performed. 
On the final pathologic examination, the right ovary showed 
a 7×6×5 cm sized tumor with a pink-yellow, soft, granular cut 
surface (Fig. 2). The tumor cells showed the typical trabecular 
pattern of HCC and had very similar features to the previously 
resected HCC mass. The tumor was compatible with metastatic 
HCC and there was no evidence of lymphovascular or perineural 
invasion. The ovarian capsule was intact and the fallopian tube 
had no tumor (Fig. 3).  
DISCUSSION
HCC rarely metastasizes to the ovary. Moreover, metastatic 
HCC should be distinguished from a hepatoid yolk sac tumor 
and a primary hepatoid carcinoma of the ovary.
10 Hepatoid 
carcinomas of the ovary and hepatoid yolk sac tumors are sus-
pected when there is no clinical or operative evidence of HCC.
Hepatoid yolk sac tumors usually occur in females of repro-
ductive age with germ cell neoplastic components or gonadal 
dysgenesis.
10 Young et al.
11 suggested that canaliculi are strong-
ly suggestive of metastatic HCC rather than hepatoid yolk sac 
tumors.
Hepatoid carcinomas of the ovary have recently been de-
scribed as a distinctive type of carcinoma that arises outside the 
liver, but to a considerable extent resembles HCC both histologi-
cally and immunohistochemically due to its staining for AFP.
11 
Hepatoid carcinomas of the ovary generally occur in older 
patients and the presence of focal staining for AFP is essential 
for a certain diagnosis of in a site as unusual as the ovary.
10 
Hepatoid carcinomas of the ovary can also present in the stom-
ach, pancreas, lungs, kidneys, and urinary bladder.
12 Because 
hepatoid carcinomas of the ovary are usually metastatic from 
the stomach and leave a lesion on the surface of the ovary, the 
existence of a hepatoid carcinoma outside the ovary and tumor 
growth on the surface of the ovary can elevate the possibility of 
a hepatoid carcinoma of the ovary. 
In the case presented herein, the patient had a history of HCC 
and there was no evidence of hepatoid carcinomas in other ab-
dominal organs. Furthermore, the pathologic features suggested 
HCC without any features of haptoid yolk sac tumors, such as 
germ cells or gonadal dysgenesis. There was also no tumor on 
the ovarian capsule or peritoneal cavity, thus the tumor was 
likely to have metastasized from the primary HCC by hematog-
Fig. 1. (A) Fusion whole-body 
positron emission tomography scan 
shows a 6-cm cystic lesion in the 
right pelvic cavity and a more focal 
hypermetabolic lesion in the inferior 
portion. (B) Abdominopelvic com-
puted tomography reveals a 7-cm 
heterogeneous mass in the right 
ovary, which suggested that meta-
static hepatocellular carcinoma was 
more likely than primary ovarian 
cancer.
Fig. 2. The gross features of the right ovarian mass. It is a 7×6×5 cm 
tumor with a pink-yellow, soft, granular cut surface.Lee JM, et al: Metastasis of Hepatocellular Carcinoma to the Ovary  545
enous spread. 
Ten cases of previously reported metastatic HCCs to the ovary 
are summarized and presented in Table 1. The mean age of the 
10 cases and the current case was 45.6 years (range, 31 to 68 
years). The number of right, left, and bilateral HCC ovarian me-
tastases were 4, 4, and 3, respectively. In 7 patients, the ovarian 
metastases were noted during follow-up, of which 3 patients 
showed no clinical symptoms or signs (case no. 1, 2, and 8). The 
other 4 patients were diagnosed as synchronous ovarian metas-
tases (case no. 3, 4, 5, and 10).
All cases were treated surgically, except 3 cases (case no. 7, 
8, and 10), which showed multiple lung, spleen, and para-aortic 
lymph node metastases (case no. 7) or peritoneal carcinomatosis 
(case no. 8 and 10). The surgical procedures performed included 
bilateral SO with or without transabdominal hysterectomy. 
In our case, we made the decision to perform a unilateral SO; 
the decision was based on the fact that there was no evidence 
of peritoneal spread or ovarian capsular involvement. In view 
of the likely hematogenous spread, a limited resection was 
performed. There was no clear oncologic evidence to support 
performing an extensive bilateral SO and hysterectomy with 
the increased risk of operative morbidity and hormonal conse-
quences. 
The recurrence of HCC can be detected by an elevated serum 
AFP or imaging findings.
13 AFP is also known as an indepen-
dent prognostic factor for HCC and a markedly elevated serum 
AFP level may reflect advanced HCC in terms of its large size or 
metastasis.
14 In our review of the 11 cases of metastatic HCC to 
the ovary (Table 1), all cases showed elevated serum AFP levels, 
except one case (case no. 6). Amongst the reported cases of HCC 
metastatic to the ovary, the serum AFP levels declined after sur-
gery and rose again when recurrence occurred (case no. 2 and 4). 
Therefore, the serum AFP can be a useful indicator of recurrent 
HCC in the ovary and should be closely observed. The serum 
AFP level did not correlate with the size of the metastatic ovar-
ian HCC, which might be due to the small sample size and the 
incomplete data set (3 of 11 patients’ data on tumor size were 
missing).
A fluorine-18 fluorodeoxyglucose (
18F-FDG) PET has a poten-
tial role in the detection of tumor recurrence of HCC patients
15-17 
because glucose metabolism assessed by 
18F-FDG PET is related 
to progression or aggressiveness of HCC.
18,19 Park et al.
20 report-
ed that a 
18F-FDG PET/CT scan has a relatively high sensitivity 
for the detection of extrahepatic metastases of HCC. In their 
data, the sensitivity of 
18F-FDG PET/CT was 60.9% for primary 
HCC and 85.7% for metastatic HCC. Further, they concluded 
Fig. 3. Microscopic features of primary hepatocellular carcinoma 
(HCC) (A) and HCC metastasis to the ovary (B, C). (A) Previously re-
sected primary HCC. The typical trabecular pattern of HCC is shown 
(x400). (B) A hypercellular nodular mass on the ovary with focal 
hemorrhage and necrosis. The ovarian cortex is intact, and no normal 
ovarian cortex is identified (x10). (C) Polygonal tumor cells with ve-
sicular nuclei and prominent nucleoli are separated by sinusoids. The 
HCC metastasized to the ovary is morphologically consistent with the 
features of primary HCC (×400).546  Gut and Liver, Vol. 5, No. 4, December 2011
that large HCC (>5 cm) had high sensitivity (92.8%). In the pres-
ent case, we also identified the site of recurrence using 
18F-FDG 
PET. Therefore, PET is a useful diagnostic modality for detecting 
the recurrence of HCC.
The diagnosis of metastatic ovarian HCC is a diagnosis of 
exclusion. In patients with a rising AFP following removal 
of primary HCC, a careful clinical assessment and abdomino-
pelvic CT should be the first line of investigation. In the absence 
of intrahepatic metastases, a chest CT and bone scan should be 
added, followed by a CT/MRI of the brain. A PET scan is a use-
ful tool in the diagnosis of extrahepatic metastasis of HCC, as 
demonstrated in our case. The ovarian metastasis can be further 
examined using pelvic US and is finally confirmed at laparoto-
my.
In conclusion, although metastasis of HCC to the ovary is 
very rare, one should have a high index of suspicion in a female 
patient with a lower abdominal mass and an elevated serum 
AFP level in the absence of other demonstrable metastases. 
Rational use of investigations such as CT or PET should help to 
confirm the diagnosis of this unusual metastasis.
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